PT - JOURNAL ARTICLE AU - Morren, John A. AU - Li, Yuebing TI - Myasthenia gravis: Frequently asked questions AID - 10.3949/ccjm.90a.22017 DP - 2023 Feb 01 TA - Cleveland Clinic Journal of Medicine PG - 103--113 VI - 90 IP - 2 4099 - http://www.ccjm.org/content/90/2/103.short 4100 - http://www.ccjm.org/content/90/2/103.full SO - Cleve Clin J Med2023 Feb 01; 90 AB - Myasthenia gravis is a disorder of neuromuscular junction transmission, the result of antibodies against the post-synaptic aspect of the neuromuscular junction. Its clinical hallmark is fatigable weakness of skeletal muscles, which tends to vary in location and severity among patients. It is treated with pyridostigmine, immunotherapy, and thymectomy. Treatment is often individualized according to disease severity, antibody status, comorbidities, and other factors. This review uses a question-and-answer format to provide up-to-date, high-yield, clinically relevant information on myasthenia gravis.